Orygen output does not change plans of Cristália

Officially, the Cristália laboratory is still part of the pharmaceutical group that joined to create the Orygen, one of the superfarmacêuticas sponsored by the federal Government to produce biologic drugs. But its output has already been settled with the other two partners, Eurofarma and Libbs, and "amicably", ensures the company's Chairman, Ogari Pacheco.
"We came to an agreement about pricing, on administrative issues. But there hasn't been a break-up with partners, like came to report. So much so that we remain partners in Eurofarma [pharmaceutical] Trumps, for example, "said Pacheco.
According to the Executive, the Cristália owns the technology that would be used by Orygen. Now, the ex-socios will have to get a new technology partner. Asked if the Government does not create restrictions on the entry of an international laboratory as supplier, Pacheco said that "If there are effective transfer of technology, shouldn't be a problem".
Pacheco praised the initiative of the federal Government of trying to create two large laboratories to perform in biotechnology, but stated that, in practice, the Union of so many companies is very difficult. "Uniting four President, leaders, with different ideas to conduct a project like this is very difficult task. It was an idyllic idea. "
Besides the Orygen, the federal Government also supported the formation of the Bionovis, a partnership between Aché laboratories, Chemical Union, EMS and Hypermarcas. The output of Cristália is the second casualty in Orygen. At the end of last year, Libbs pharmaceutical had already left the company. Now Eurofarma and Biolab should touch the project alone. The Government's original idea was to unite the eight laboratory on a single company, but that proved impossible early in the project.
Pacheco said the Cristália will keep investments that was already doing in biotechnology. He opened a factory last month in Itapira (SP), and is building a second unit on the same ground. "To date, we have invested around r $ 120 million in the two units. We're not going to stop our work, "assured.
For the President of Cristália, competition from four groups working in biotechnology-Cristália, Orygen, Biolab and Libbs-will be positive for the market and for the country. If the Government wanted to boost exploration and production with both superfarmacêuticas, now have four groups promising to invest in the segment.